Agilent could benefit significantly as AI adoption in drug discovery and life sciences boosts demand for research infrastructure. Strong free cash flow and an improving EPS outlook accompany its massive five-year base; the larger base points to greater upside. x.com 

Danaher's rebound looks like one to fade near $190 because bioprocessing, its bigger business, delivered disappointing sales and guidance. Weak trading in peers, with Repligen also lower, echoed that. A move from $165 to $190 in two days seems off; the initial flush may have been overdone, but it is hard to argue Danaher deserves to trade back at $200, where it entered earnings, after that bioprocessing commentary. x.com 

Iambic's R&D split and the basket's returns show why data-generating lab work matters more than compute in applied AI biotech. Iambic's S-1 puts about 8 cents of its 2025 R&D dollar into compute, 31 into discovery and the lab, and 28.5 into the clinic. After two months, the basket rose 20.5% versus -0.2% for the S&P 500 and -4.8% for biotech. Data-producing names rose 33.5%, or 16.8% without Moderna's readout day, versus 9% for bioprocess and reagents. The market bought the data. x.com 

Bruker's 20% drop on an unremarkable quarter looks overdone, and about half that loss should recover quickly. Its technology is incredible even if management is less than stellar, and eventually the technology is all that will matter. The AI-driven biotech capital spending boom has yet to arrive after Trump-administration cuts, and the inflection should be huge; as AI showed, buyers fight for scarce equipment at multiples of prior prices, so any AI aspirant should want a piece of Bruker. x.com  … Show more

AI-enabled drug discovery is the next re-rate, because if AI raises lab hit rates, the cost of failure falls across the sector and beaten-down platforms re-rate first. Recursion is the cleanest expression, an AI-first platform built to industrialize discovery. AbCellera and Tempus apply AI to antibody discovery and the diagnostics data layer, with real revenue under the story. The trap is paying a winner's multiple before the trial proves the winner. x.com 

Danaher is a cleaner way than Thermo Fisher to play an aging population. Its greater bioprocessing exposure ties it more directly to drug cost of goods. x.com 

Danaher looks like a highly asymmetric buy after its selloff because it is likely to post revenue growth in 2027 and 2028. x.com 

Danaher's Masimo deal can create far more value than its high-single-digit Year 5 ROIC target suggests, because it pays a similar EBITDA multiple for a faster-compounding earnings stream. The target means about an 8% Year 5 unlevered FCF yield on the $9.9B entry EV. Counting cash generated and terminal value, with $125M cost and $50M revenue synergies, IRR could be about 22%, high teens even before synergies. The topline case is aggressive, but Danaher's DBS record supports the synergies. x.com  … Show more

High-quality, non-cyclical compounders like Visa, Mastercard, FICO and S&P Global trade alike because they share a durable-moat logic, and that assumption will likely prove correct long term for many of them. Investors reasoned that durable returns on capital, high growth and a low cost of capital justified almost any multiple while the moat held. Capital following that logic is pulling back, partly on flows and partly on AI terminal-value worries, so the group sells off together. x.com  x.com 

Bioprocessing suppliers gain a new demand tailwind as antibody drugs shift from IV to subcutaneous injectables, per @Borlaug_. SubQ could add 1-3% to bioprocess demand growth over 5-10 years, and one drug that added a subQ version in 2025 is on track to add 150bps to industry volume in 2027. Antibodies are 85%+ of bioprocess sales at Danaher, Thermo Fisher, Sartorius, Sartorius Stedim and Repligen, and their volume grows 6-7% a year, supporting a high-single-digit floor for consumables growth. … Show more